LEFAMULIN

Lefamulin (formerly known as BC-3781) is a semi-synthetic
pleuromutilin mainly studied for CABP and acute bacterial skin and skin-structure infections (ABSSSIs).

Lefamulin has a novel mechanism of action of selective binding to the peptidyl transferase center (PTC) of the 50S ribosomal subunit to prevent bacterial protein synthesis

The spectrum of activity of lefamulin covers Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA), as well as Moraxella catarrhalis, Haemophilus influenzae, and atypical pathogens such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila.

Two phase III studies (LEAP1 and LEAP2 trials) have tested the safety and efficacy of lefamulin in adult patients with CABP.

On 19 August 2019, the U.S. Food and Drug Administration (FDA) announced the approval of lefamulin for the treatment of adult community-acquired bacterial pneumonia (CABP).



Comments

Popular posts from this blog

HYPOTHYROIDISM CLINICAL FEATURES

Congenital Hypertrophic Pyloric Stenosis

Febrile Seizure: Review